Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

2018

Journal of Clinical Oncology , Volume 36 - Issue 20 p. 2035- +

Additional Metadata
Persistent URL	doi.org/10.1200/jco.2017.76.1742, hdl.handle.net/1765/114798
Journal	Journal of Clinical Oncology
Organisation	Department of Radiation Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Dimopoulos, M., Weisel, K, van de Donk, N, Ramasamy, K., Gamberi, B, Streetly, M., … Sonneveld, P. (2018). Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Journal of Clinical Oncology, 36(20), 2035–+. doi:10.1200/jco.2017.76.1742

Publication